These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35839733)

  • 1. Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer.
    Kim CG; Hong M; Jeung HC; Lee G; Chung HC; Rha SY; Kim HS; Lee CK; Lee JH; Han Y; Kim JH; Lee SY; Kim H; Shin SJ; Baek SE; Jung M
    Eur J Cancer; 2022 Sep; 172():387-399. PubMed ID: 35839733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma.
    Kim CG; Kim C; Yoon SE; Kim KH; Choi SJ; Kang B; Kim HR; Park SH; Shin EC; Kim YY; Kim DJ; Chung HC; Chon HJ; Choi HJ; Lim HY
    J Hepatol; 2021 Feb; 74(2):350-359. PubMed ID: 32810553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer.
    Aoki M; Shoji H; Nagashima K; Imazeki H; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Higuchi K; Boku N
    ESMO Open; 2019; 4(3):e000488. PubMed ID: 31231567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
    Ferrara R; Mezquita L; Texier M; Lahmar J; Audigier-Valette C; Tessonnier L; Mazieres J; Zalcman G; Brosseau S; Le Moulec S; Leroy L; Duchemann B; Lefebvre C; Veillon R; Westeel V; Koscielny S; Champiat S; Ferté C; Planchard D; Remon J; Boucher ME; Gazzah A; Adam J; Bria E; Tortora G; Soria JC; Besse B; Caramella C
    JAMA Oncol; 2018 Nov; 4(11):1543-1552. PubMed ID: 30193240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer.
    Kas B; Talbot H; Ferrara R; Richard C; Lamarque JP; Pitre-Champagnat S; Planchard D; Balleyguier C; Besse B; Mezquita L; Lassau N; Caramella C
    JAMA Oncol; 2020 Jul; 6(7):1039-1046. PubMed ID: 32525513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer.
    Sasaki A; Nakamura Y; Mishima S; Kawazoe A; Kuboki Y; Bando H; Kojima T; Doi T; Ohtsu A; Yoshino T; Kuwata T; Akimoto T; Shitara K
    Gastric Cancer; 2019 Jul; 22(4):793-802. PubMed ID: 30627987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperprogressive Disease (HPD) in Solid Tumours Receiving Immune Checkpoint Inhibitors in a Real-World Setting.
    Kanjanapan Y; Guduguntla G; Varikara AK; Szajer J; Yip D; Cockburn J; Fadia M
    Technol Cancer Res Treat; 2023; 22():15330338231209129. PubMed ID: 37885403
    [No Abstract]   [Full Text] [Related]  

  • 8. Hyperprogressive Disease Caused by PD-1 Inhibitors for the Treatment of Pan-Cancer.
    Chen S; Gou M; Yan H; Fan M; Pan Y; Fan R; Qian N; Dai G
    Dis Markers; 2021; 2021():6639366. PubMed ID: 34239621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperprogressive disease during PD-1 blockade in patients with advanced pancreatic cancer.
    Chen S; Han L; Guo S; Tan Z; Dai G
    Hum Vaccin Immunother; 2023 Aug; 19(2):2252692. PubMed ID: 37675466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proposal for multiple new lesions as complement of hyperprogressive disease in NSCLC patients treated with PD-1/PD-L1 immunotherapy.
    Wang M; Huang H; Xu Z; Li Z; Shen L; Yu Y; Lu S
    Lung Cancer; 2022 Nov; 173():28-34. PubMed ID: 36116167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.
    Champiat S; Dercle L; Ammari S; Massard C; Hollebecque A; Postel-Vinay S; Chaput N; Eggermont A; Marabelle A; Soria JC; Ferté C
    Clin Cancer Res; 2017 Apr; 23(8):1920-1928. PubMed ID: 27827313
    [No Abstract]   [Full Text] [Related]  

  • 12. Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors.
    Hwang I; Park I; Yoon SK; Lee JL
    Clin Genitourin Cancer; 2020 Apr; 18(2):e122-e133. PubMed ID: 31837940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.
    Matos I; Martin-Liberal J; García-Ruiz A; Hierro C; Ochoa de Olza M; Viaplana C; Azaro A; Vieito M; Braña I; Mur G; Ros J; Mateos J; Villacampa G; Berché R; Oliveira M; Alsina M; Elez E; Oaknin A; Muñoz-Couselo E; Carles J; Felip E; Rodón J; Tabernero J; Dienstmann R; Perez-Lopez R; Garralda E
    Clin Cancer Res; 2020 Apr; 26(8):1846-1855. PubMed ID: 31757877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory T cells as crucial trigger and potential target for hyperprogressive disease subsequent to PD-1/PD-L1 blockade for cancer treatment.
    Ren Z; Yang K; Zhu L; Yin D; Zhou Y
    Int Immunopharmacol; 2024 May; 132():111934. PubMed ID: 38574701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperprogression, a challenge of PD-1/PD-L1 inhibitors treatments: potential mechanisms and coping strategies.
    Zhao LP; Hu JH; Hu D; Wang HJ; Huang CG; Luo RH; Zhou ZH; Huang XY; Xie T; Lou JS
    Biomed Pharmacother; 2022 Jun; 150():112949. PubMed ID: 35447545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan.
    Aoki M; Kadowaki S; Takahashi N; Suzuki T; Oshima K; Ando T; Yamamoto Y; Kawakami K; Kito Y; Matsumoto T; Shimozaki K; Miyazaki Y; Yamaguchi T; Nagase M; Tamura T; Amanuma Y; Esaki T; Miura Y; Akiyoshi K; Baba E; Makiyama A; Negoro Y; Nakashima K; Sugimoto N; Nagashima K; Shoji H; Boku N
    Gastric Cancer; 2023 Jan; 26(1):132-144. PubMed ID: 36316527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1
    Kamada T; Togashi Y; Tay C; Ha D; Sasaki A; Nakamura Y; Sato E; Fukuoka S; Tada Y; Tanaka A; Morikawa H; Kawazoe A; Kinoshita T; Shitara K; Sakaguchi S; Nishikawa H
    Proc Natl Acad Sci U S A; 2019 May; 116(20):9999-10008. PubMed ID: 31028147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs).
    Liu J; Wu Q; Wu S; Xie X
    Clin Transl Oncol; 2021 Sep; 23(9):1782-1793. PubMed ID: 33847923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting hyperprogressive disease in patients with advanced hepatocellular carcinoma treated with anti-programmed cell death 1 therapy.
    Zhang L; Wu L; Chen Q; Zhang B; Liu J; Liu S; Mo X; Li M; Chen Z; Chen L; You J; Jin Z; Chen X; Zhou Z; Zhang S
    EClinicalMedicine; 2021 Jan; 31():100673. PubMed ID: 33554079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term Follow-up and Patterns of Response, Progression, and Hyperprogression in Patients after PD-1 Blockade in Advanced Sarcoma.
    Klemen ND; Hwang S; Bradic M; Rosenbaum E; Dickson MA; Gounder MM; Kelly CM; Keohan ML; Movva S; Thornton KA; Chi P; Nacev BA; Chan JE; Bartlett EK; Richards AL; Singer S; Donoghue MTA; Tap WD; D'Angelo SP
    Clin Cancer Res; 2022 Mar; 28(5):939-947. PubMed ID: 34965948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.